



3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

**Patient Name:** Patient, Name**Specimen ID (SID):** 25-001-0000**DOB:** 01-Jan-2000**PHN:** AB 0000000**Reason for Testing:** Spinal lesions**Relevant Medications:** -**External SID:** 123456789**Doctor:** Dr. Doctor**Report Date:** 12-Mar-2025**Specimen Type:** CSF**Date/Time Collected:** 01-Jan-2025 / 00:00**Specimen Source:** MitogenDx**Soluble Cytokine Receptor Panel****Laboratory Developed Test (LDT)**

Analyte	Results (pg/ml)	Reference Interval†
sCD30*	28.6 HIGH	0 - 24.4
sEGFR	3520	2904 - 7261
sgp130	27681	16464 - 49646
sIL-1RI	13.0 HIGH	2.7 - 12.9
sIL-1RII	< 244	0 - 244
sIL-2Rα	42.5 HIGH	0 - 19.6
sIL-4R*	< 48.8	0 - 48.8
sIL-6R	1107	520 - 1286
sRAGE	2.7	1.6 - 2.7
sTNFRI	427	361 - 994
sTNFRII	1569	503 - 1907
sVEGFR1	80.5	0 - 203
sVEGFR2	910	569 - 1579
sVEGFR3*	< 30.5	0 - 30.5

Sample Comments:

-

Results Interpretation:

Possible abnormalities have been detected in TNF family signaling (sCD30), IL-1 signaling (sIL-1RI), T cell activation (sIL-2Rα), IL-6 trans-activation (sIL-6R - moderate high), and RAGE-mediated inflammatory signaling (sRAGE).

Disclaimer:

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

Reviewed by: DP**Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory**

† Reference intervals defined as the 15th percentile (low) and 85th percentile (high) of the total sample distribution.

* Upper reference limit defined as the lower limit of quantification (LLOQ) for this analyte.